Relapsed refractory multiple myeloma
2 papers study it1 more mentions it
- Humans2
Trial sponsors
Company2 trialsPhase 4440 people
Company2 trialsPhase 4275 people
Company5 trialsPhase 3791 people
Company1 trialPhase 3508 people
Company1 trialPhase 3360 people
Company1 trialPhase 3255 people
Company1 trialPhase 354 people
Company1 trialPhase 2118 people
Latest
Journal of Geriatric Oncology
Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index
Cross-sectional study of 511 peopleMultiple myeloma
Journal of Geriatric Oncology
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty
Cohort study of 2,750 peopleBiomarkers
The Lancet Healthy Longevity
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Cross-sectional study of 415 peopleMultiple myeloma